Industry, FDA Coordination Key To Diagnostic Test Availability – McClellan
This article was originally published in The Gray Sheet
Executive Summary
FDA and CDC will coordinate efforts to provide standardized specimens of severe acute respiratory syndrome (SARS) to manufacturers by year-end to aid in validating diagnostics for the disease
You may also be interested in...
FDA, CDC Address Disease Outbreak Test Development In Wake Of SARS
The investigational device exemption process for diagnostic tests related to disease outbreaks should be expedited, FDA acknowledges
NIH, FDA Respond To SARS Epidemic: Diagnostics, Medical Supply Stockpile
A sensitive and specific diagnostic for severe acute respiratory syndrome will be available in six to 12 months, NIAID Director Anthony Fauci, MD, averred at a May 7 House Energy & Commerce/Oversight & Investigations Subcommittee hearing
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.